139 related articles for article (PubMed ID: 28008195)
1. A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: An initial 5-year analysis.
Itoh Y; Kubota S; Kawamura M; Nomoto Y; Murao T; Yamakawa K; Ishihara S; Hirasawa N; Asano A; Yanagawa S; Naganawa S
Nagoya J Med Sci; 2016 Dec; 78(4):399-406. PubMed ID: 28008195
[TBL] [Abstract][Full Text] [Related]
2. Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy.
Oie Y; Itoh Y; Kawamura M; Takase Y; Murao T; Ishihara S; Nomoto Y; Hirasawa N; Asano A; Yamakawa K; Ito J; Kinoshita F; Naganawa S
Nagoya J Med Sci; 2021 Nov; 83(4):811-825. PubMed ID: 34916724
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction.
Lee TH; Lee JH; Kwon SK; Chung EJ; Wu HG
Radiat Oncol J; 2022 Jun; 40(2):120-126. PubMed ID: 35796115
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of radiation therapy for T1 glottic carcinoma from an Italian regional series with doses ranging from 60 to 66 Gy.
Manzo R; Ravo V; Murino P; Morra A; Panetti G; Laudati A; Prisco A; Panelli G; Muto P
Tumori; 2010; 96(4):577-81. PubMed ID: 20968137
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).
Kouloulias VE; Zygogianni A; Mosa E; Platoni K; Georgakopoulos J; Antypas C; Beli I; Tolia M; Maragoudakis P; Giotakis I; Papas Z; Psyrri A; Kelekis N; Kouvaris J
Radiol Oncol; 2013 Jun; 47(2):185-91. PubMed ID: 23801916
[TBL] [Abstract][Full Text] [Related]
6. Optimized treatment strategy of radiotherapy for early glottic squamous cell carcinomas: An initial analysis.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Naganawa S
Nagoya J Med Sci; 2017 Aug; 79(3):331-338. PubMed ID: 28878438
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
[TBL] [Abstract][Full Text] [Related]
8. 3D conformal hypofractionated radical radiotherapy in early glottic cancer.
Amado AC; Bujor L; Monteiro Grillo I
Rep Pract Oncol Radiother; 2013 May; 18(5):261-4. PubMed ID: 24416562
[TBL] [Abstract][Full Text] [Related]
9. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
[TBL] [Abstract][Full Text] [Related]
10. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. Optimized radiotherapy treatment strategy for early glottic carcinoma.
Ono T; Itoh Y; Ishihara S; Kawamura M; Oie Y; Takase Y; Okumura M; Oyoshi H; Nagai N; Naganawa S
Nagoya J Med Sci; 2023 May; 85(2):241-254. PubMed ID: 37346844
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy.
Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Sakurada A; Sugahara S; Park J; Tokuuye K; Saito K
Mol Clin Oncol; 2020 Jun; 12(6):541-550. PubMed ID: 32337036
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.
Karasawa K; Kunogi H; Hirai T; Hoji H; Hirowatari H; Izawa H; Ito K; Sasai K; Furuya T; Ozawa S; Matsumoto F; Ito S; Oba S
J Radiat Res; 2013 Jul; 54(4):684-9. PubMed ID: 23297315
[TBL] [Abstract][Full Text] [Related]
15. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Hirakawa A; Naganawa S
Asian Pac J Cancer Prev; 2018 May; 19(5):1195-1199. PubMed ID: 29801401
[TBL] [Abstract][Full Text] [Related]
16. Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?
Garden AS; Forster K; Wong PF; Morrison WH; Schechter NR; Ang KK
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):322-8. PubMed ID: 12527044
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
18. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.
Salas-Salas BG; Domínguez-Nuez DJ; Cabrera R; Ferrera-Alayón L; Lloret M; Lara PC
Clin Transl Oncol; 2020 Jan; 22(1):151-157. PubMed ID: 31152306
[TBL] [Abstract][Full Text] [Related]
20. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]